Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | HTR1A | P08908 | 7/20 | 0.58 |
| ▸ | HTR7 | P34969 | 7/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14094445 | 0.86 | SMN1; SMN2 (0.56) | MAPK1HTTHTR1AHTR7SMN1; SMN2 | |
| SCHEMBL13200796 | 0.86 | ALDH1A1 (0.69) | HTTSMN1; SMN2KDM4ERECQLALDH1A1 | |
| SCHEMBL1659340 | 0.85 | MAPK1 (0.83) | MAPK1HTTHTR1AHTR7SMN1; SMN2 | |
| SCHEMBL5245677 | 0.84 | MCOLN2 (0.61) | HTTHTR1AHTR7SMN1; SMN2KDM4E | |
| SCHEMBL23052382 | 0.83 | HTT (0.65) | MAPK1HTTHTR1AHTR7SMN1; SMN2 | |
| SCHEMBL2547923 | 0.82 | SMN1; SMN2 (0.51) | MAPK1HTTSMN1; SMN2KDM4ERECQL | |
| SCHEMBL14923992 | 0.82 | USP30 (0.64) | HTTHTR1AHTR7SMN1; SMN2KDM4E | |
| SCHEMBL3013547 | 0.82 | MAPK1 (0.90) | MAPK1HTTSMN1; SMN2KDM4ERECQL | |
| SCHEMBL1134916 | 0.81 | KDM4E (0.50) | HTTHTR1AHTR7SMN1; SMN2KDM4E | |
| SCHEMBL16222301 | 0.81 | KMT2A (0.56) | SMN1; SMN2KDM4ERECQLALDH1A1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3786156-A1 | 10H-PHENOTHIAZINE FERROPTOSIS INHIBITOR AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Chengdu Henghao Investment Co. Limited (CN) | 2021-03-03 | — | — | EP | disclosed |
| US-20210040079-A1 | 10H-phenothiazine ferroptosis inhibitor as well as the preparative method and the use thereof | Chengdu Henghao Investment Co. Limited (CN) | 2021-02-11 | — | — | US | disclosed |
| US-20090105252-A1 | Pyrimidine Derivatives and Their Use in Therapy as well as the Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105252-A1 | Pyrimidine Derivatives and Their Use in Therapy as well as the Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105252-A1 | Pyrimidine Derivatives and Their Use in Therapy as well as the Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| EP-1945628-A1 | NEW PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY AS WELL AS THE USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER'S DISEASE | AstraZeneca AB (SE) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007040440-A1 | NEW PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY AS WELL AS THE USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER’S DISEASE | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007040440-A1 | NEW PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY AS WELL AS THE USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER’S DISEASE | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040079-A1 | 10H-phenothiazine ferroptosis inhibitor as well as the preparative method and the use thereof | AIFM2, FECH, GPX4 | MAPK1 3023/4885HTT 1784/4885HTR1A 1473/4885 |
| US-20090105252-A1 | Pyrimidine Derivatives and Their Use in Therapy as well as the Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease | DPYD, TYMS, TYMP | MAPK1 2594/4885HTT 440/4885HTR1A 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.